menu
    • menu

    Company profile for Foghorn Therapeutics

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic ControlTM Product Platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us – and rewrite destiny for millions...
    Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic ControlTM Product Platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us – and rewrite destiny for millions of people living with disease. With the Gene Traffic ControlTM Product Platform, Foghorn® Therapeutics is discovering and developing an unprecedented class of medicines targeting diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Foghorn TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    100 Binney Street, Suite 610, Cambridge, MA 02142
    Telephone
    Telephone
    617-586-3100
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://foghorntx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/foghorn-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Foghorn Presents Data on FHD-909 Degraders at AACR 2026
    Foghorn Presents Data on FHD-909 Degraders at AACR 2026

    21 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/21/3278403/0/en/foghorn-therapeutics-presents-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-for-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting.html

    GLOBENEWSWIRE
    21 Apr 2026
    Share Share
    Foghorn Therapeutics Presents FHD-909 Data at 2026 AACR
    Foghorn Therapeutics Presents FHD-909 Data at 2026 AACR

    09 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/09/3270778/0/en/Foghorn-Therapeutics-to-Present-New-Preclinical-Data-for-Selective-SMARCA2-Inhibitor-FHD-909-and-Selective-CBP-EP300-and-ARID1B-Degrader-Programs-at-the-2026-AACR-Annual-Meeting.html

    GLOBENEWSWIRE
    09 Apr 2026
    Share Share
    Foghorn Therapeutics Shares 2025-26 Financial and Strategic Plans
    Foghorn Therapeutics Shares 2025-26 Financial and Strategic Plans

    11 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/11/3254140/0/en/Foghorn-Therapeutics-Provides-Financial-Update-for-2025-and-2026-Strategic-Outlook.html

    GLOBENEWSWIRE
    11 Mar 2026
    Share Share
    Foghorn Therapeutics To Join Two Investor Conferences
    Foghorn Therapeutics To Join Two Investor Conferences

    24 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/24/3243365/0/en/Foghorn-Therapeutics-to-Participate-in-Two-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    24 Feb 2026
    Share Share
    Foghorn Therapeutics Appoints Ryan Maynard As CFO
    Foghorn Therapeutics Appoints Ryan Maynard As CFO

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/23/3242457/0/en/Foghorn-Therapeutics-Strengthens-Financial-Leadership-with-Appointment-of-Ryan-Maynard-as-Chief-Financial-Officer.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    Yatiri Bio Predicts AML Drug Response With Foghorn's FHD-286
    Yatiri Bio Predicts AML Drug Response With Foghorn's FHD-286

    10 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/10/3235109/0/en/Yatiri-Bio-Accurately-Predicts-AML-Drug-Response-in-Blinded-Study-Using-Foghorn-s-FHD-286.html

    GLOBENEWSWIRE
    10 Feb 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search